The outcome of donor screening for Human T-Cell Lymphotropic Virus infection in the Netherlands

Vox Sanguinis

Volumn 102, Issue 3, 2012, Pages 198-203

  Prinsze, F J ^a   Zaaijer, H L ^a  

^a CENTRAL LABORATORY   (Netherlands)

Author keywords

Blood donor screening; Human T Cell Lymphotropic virus; Leucodepletion

Indexed keywords

ARTICLE; BLOOD DONOR; ERYTHROCYTE TRANSFUSION; HEALTH CARE COST; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCREENING; THROMBOCYTE TRANSFUSION; VIRUS TRANSMISSION;

BLOOD DONORS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; DONOR SELECTION; FEMALE; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; MALE; NETHERLANDS; RETROSPECTIVE STUDIES;

EID: 84858293976     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01538.x     Document Type: Article

References (30)

1. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, et al.: Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005; 24:6058-6068
2. Roucoux DF, Murphy EL: The epidemiology and disease outcomes of human T-lymphotropic virus type II. AIDS Rev 2004; 6:144-154
3. Okochi K, Sato H: Transmission of adult T-cell leukaemia virus (HTLV-I) through blood transfusion and its prevention. AIDS Res 1986; 2(Suppl. 1):S157-S161
4. Laperche S, Worms B, Pillonel J: Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009; 96:104-110
5. Mayer V, Ebbesen P: HTLV-I virus in Europeans: the continuous spread. A meta-analysis. Acta Virol 1991; 35:472-495
6. Okochi K, Sato H, Hinuma Y: A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984; 46:245-253
7. Tynell E, Andersson S, Lithander E, et al.: Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis. BMJ 1998; 316:1417-1422
8. Wenz B, Ortolano GA: Leukocyte reduction and HTLV-I: is the glass half empty or half full? Blood 2003; 101:370
9. Zaaijer HL, Dudok de Wit C, Cuypers HTM, et al.: [The prevalence of human T-lymphotropic virus type I among Dutch blood donors]. Ned Tijdschr Geneeskd 1993; 137:2541-2543
10. Zaaijer HL, Lelie PN, Van der Poel CL: [Infection with T-lymphotropic virus in Dutch blood donors, 1993-1996]. Ned Tijdschr Geneeskd 1997; 141:1571-1572
11. Shinzato O, Ikeda S, Momita S, et al.: Semiquantitative analysis of integrated genomes of human T-lymphotropic virus type I in asymptomatic virus carriers. Blood 1991; 78:2082-2088
12. Pennington J, Taylor GP, Sutherland J, et al.: Persistence of HTLV-I in blood components after leukocyte depletion. Blood 2002; 100:677-681
13. Cesaire R, Kerob-Bauchet B, Bourdonne O, et al.: Evaluation of HTLV-I removal by filtration of blood cell components in a routine setting. Transfusion 2004; 44:42-48
14. Gout O, Baulac M, Gessain A, et al.: Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 1990; 322:383-388
15. Sullivan MT, Williams AE, Fang CT, et al.: Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988). The American Red Cross HTLV-I/II Collaborative Study Group. Arch Intern Med 1991; 151:2043-2048
16. Manns A, Wilks RJ, Murphy EL, et al.: A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51:886-891
17. Borkent-Raven BA, Janssen MP, Van der Poel CL, et al.: The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sang 2010; 99:55-64
18. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, et al.: Survival after blood transfusion. Transfusion 2008; 48:2577-2584
19. Verdonck K, Gonzalez E, Van Dooren S, et al.: Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Lancet Infect Dis 2007; 7:266-281
20. Sanquin Blood Foundation. [Faces of 2008. Annual Report]: Amsterdam, the Netherlands. Sanquin Blood Supply Foundation. June, 2009
21. World Health Organization: Threshold Values for Intervention Cost Effectiveness by Region. Geneva, Switzerland, 2000
22. Custer B, Hoch JS: Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009; 23:1-12
23. van Hulst M, De Wolf JT, Staginnus U, et al.: Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83:146-155
24. Namen-Lopes MS, Martins ML, Drummond PC, et al.: Lookback study of HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil. Transfus Med 2009; 19:180-188
25. Stramer SL, Foster GA, Dodd RY: Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004. Transfusion 2006; 46:703-707
26. Cesaire R, Bera O, Maier H, et al.: Seroindeterminate patterns and seroconversions to human T-lymphotropic virus type I positivity in blood donors from Martinique, French West Indies. Transfusion 1999; 39:1145-1149
27. Rios M, Khabbaz RF, Kaplan JE, et al.: Transmission of human T cell lymphotropic virus (HTLV) type II by transfusion of HTLV-I-screened blood products. J Infect Dis 1994; 170:206-210
28. Davidson F, Lycett C, Jarvis LM, et al.: Detection of HTLV-I and -II in Scottish blood donor samples and archive donations. Vox Sang 2006; 91:231-236
29. DePalma L, Luban NL: Transmission of human T-lymphotrophic virus type I infection to a neonatal infant by transfusion of washed and irradiated red cells. Transfusion 1993; 33:582-584
30. Kleinman S, Swanson P, Allain JP, et al.: Transfusion transmission of human T-lymphotropic virus types I and II: serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion 1993; 33:14-18